Literature DB >> 27576587

Assessing the impact of defining a global priority research agenda to address HIV-associated tuberculosis.

Anna Odone1,2, Alberto Matteelli3, Valentina Chiesa4, Paola Cella4, Antonio Ferrari4, Federica Pezzetti4, Carlo Signorelli4,5, Haileyesus Getahun6.   

Abstract

OBJECTIVES: In 2010, the WHO issued 77 priority research questions (PRQs) to address HIV-associated TB. Objective of the this study was to assess the impact of defining the research agenda in stimulating and directing research around priority research questions.
METHODS: We used number and type of scientific publications as a proxy to quantitatively assess the impact of research agenda setting. We conducted 77 single systematic reviews - one for every PRQ - building 77 different search strategies using PRQs' keywords. Multivariate logistic regression models were applied to assess the quantity and quality of research produced over time and accounting for selected covariates.
RESULTS: In 2009-2015, PRQs were addressed by 1631 publications (median: 11 studies published per PRQ, range 1-96). The most published area was 'Intensified TB case finding' (median: 23 studies/PRQ, range: 2-74). The majority (62.1%, n = 1013) were published as original studies, and more than half (58%, n = 585) were conducted in the African region. Original studies' publication increased over the study period (P trend = <0.001). They focused more on the 'Intensified TB case finding' (OR = 2.17, 95% CI: 1.56-2.93) and 'Drug-resistant TB and HIV infection' (OR = 2.12, 95% CI: 1.47-3.06) areas than non-original studies. Original studies were published in journals of lower impact factor and received a smaller number of citations than non-original studies (OR = 0.54, 95% CI: 0.42-0.69).
CONCLUSION: The generation of evidence to address PRQs has increased over time particularly in selected fields. Setting a priority research agenda for HIV-associated TB might have positively influenced the direction and the conduct of research and contributed to the global response to such a major threat to health.
© 2016 John Wiley & Sons Ltd.

Entities:  

Keywords:  HIV-associated TB; OMS; PLHIV; TB asociada al VIH; TB associée au VIH; TB-HIV co-infection; WHO; coinfección TB-VIH; coinfection TB-VIH; establecimiento de prioridades; investigación; personas viviendo con VIH; personnes vivant avec le VIH; recherche; research priority setting; revisión sistemática; revue systématique; systematic review; établissement des priorités

Mesh:

Year:  2016        PMID: 27576587     DOI: 10.1111/tmi.12768

Source DB:  PubMed          Journal:  Trop Med Int Health        ISSN: 1360-2276            Impact factor:   2.622


  4 in total

1.  Assessment of recombinant plasmid expressing fusion antigen Ag85B-Rv3425 in management of acute tuberculosis infection in mice.

Authors:  Huichang Huang; Feifei Wang; Enzhuo Yang; Honghai Wang; Peng Gao; Hongbo Shen
Journal:  Exp Ther Med       Date:  2018-01-23       Impact factor: 2.447

2.  Identifying research questions for HIV, tuberculosis, tuberculosis-HIV, malaria, and neglected tropical diseases through the World Health Organization guideline development process: a retrospective analysis, 2008-2018.

Authors:  S Hargreaves; J Himmels; L B Nellums; G Biswas; A F Gabrielli; N Gebreselassie; M Zignol; D Schellenberg; S L Norris; N Ford; D Maher
Journal:  Public Health       Date:  2020-09-01       Impact factor: 2.427

Review 3.  A scoping review on research agendas to enhance prevention of epidemics and pandemics in Africa.

Authors:  Jill Ryan; Alison Wiyeh; Humphrey Karamagi; Joseph Okeibunor; Prosper Tumusiime; Charles Shey Wiysonge
Journal:  Pan Afr Med J       Date:  2020-11-24

4.  Setting Global Research Priorities in Pediatric and Adolescent HIV Using the Child Health and Nutrition Research Initiative (CHNRI) Methodology.

Authors:  Cadi Irvine; Alice Armstrong; Jason M Nagata; Nigel Rollins; Diddie Schaaf; Meg Doherty; Martina Penazzato; Marissa Vicari
Journal:  J Acquir Immune Defic Syndr       Date:  2018-08-15       Impact factor: 3.731

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.